Cargando…
Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has emerged as a global pandemic that upended existing protocols and practices, including those for allogeneic hematopoietic stem cell transplantation (HCT). Here, we describe the su...
Autores principales: | Pourhassan, Hoda, La Rosa, Corinna, Chiuppesi, Flavia, Puing, Alfredo, Aldoss, Ibrahim, Park, Yoonsuh, Zhou, Qiao, Karpinski, Veronica, Faircloth, Katelyn, Kaltcheva, Teodora, Johnson, Daisy, Francisco, Sandra Ortega, Zaia, John A., Nakamura, Ryotaro, Al Malki, Monzr M., Diamond, Don J., Dadwal, Sanjeet Singh, Forman, Stephen J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8752192/ https://www.ncbi.nlm.nih.gov/pubmed/35008104 http://dx.doi.org/10.1182/bloodadvances.2021006282 |
Ejemplares similares
-
Putative Protective Role of Sars-Cov-2-Specific T Cells in an HCT Patient Transplanted during Active COVID19 Infection
por: Pourhassan, Hoda, et al.
Publicado: (2022) -
Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants
por: Chiuppesi, Flavia, et al.
Publicado: (2022) -
Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study
por: La Rosa, Corinna, et al.
Publicado: (2023) -
Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy
por: Chiuppesi, Flavia, et al.
Publicado: (2023) -
Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial
por: Chiuppesi, Flavia, et al.
Publicado: (2022)